Mr. Doug Drysdale reports

CYBIN ANNOUNCES ADDITIONAL U.S. PATENT SUPPORTING ITS CYB003 BREAKTHROUGH THERAPY PROGRAM IN PHASE 3 DEVELOPMENT FOR MAJOR DEPRESSIVE DISORDER

Cybin Inc. has received notice that the United States Patent and Trademark Office has granted U.S. patent 12,291,499 in support of its CYB003 program in MDD.

The patent, which is expected to provide exclusivity until 2041, includes claims to pharmaceutical compositions and oral dosage forms within the company's proprietary deuterated psilocin analog program, CYB003.

"Securing an additional patent in support of CYB003 provides important validation of our program and reinforces the commercial potential of our pipeline," said Doug Drysdale, chief executive officer of Cybin. "Robust patent protection is essential for drug development companies, and we are proud of our expanding intellectual property portfolio. As we continue to dose patients in our first Phase 3 study, we are focused on execution, delivering shareholder value, and ultimately, creating more effective treatments for those with mental health disorders."

About Cybin Inc.

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental health care by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

We seek Safe Harbor.